4.8 Review

Targeting microRNAs in cancer: rationale, strategies and challenges

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 9, Issue 10, Pages 775-789

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3179

Keywords

-

Funding

  1. NATIONAL CANCER INSTITUTE [P50CA140158] Funding Source: NIH RePORTER
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL104460] Funding Source: NIH RePORTER
  3. NCI NIH HHS [P50 CA140158] Funding Source: Medline
  4. NHLBI NIH HHS [R21 HL104460] Funding Source: Medline

Ask authors/readers for more resources

MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that regulate gene expression. Early studies have shown that miRNA expression is deregulated in cancer and experimental data indicate that cancer phenotypes can be modified by targeting miRNA expression. Based on these observations, miRNA-based anticancer therapies are being developed, either alone or in combination with current targeted therapies, with the goal to improve disease response and increase cure rates. The advantage of using miRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. In this Review, we describe the role of miRNAs in tumorigenesis and critically discuss the rationale, the strategies and the challenges for the therapeutic targeting of miRNAs in cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available